CRSwNP术后复发与中医证型及组织炎性细胞浸润类型相关性的前瞻性研究

注册号:

Registration number:

ITMCTR2100004599

最近更新日期:

Date of Last Refreshed on:

2021-01-01

注册时间:

Date of Registration:

2021-01-01

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

CRSwNP术后复发与中医证型及组织炎性细胞浸润类型相关性的前瞻性研究

Public title:

A prospective study on the correlation between postoperative recurrence of CRSwNP and TCM syndrome types and tissue inflammatory cell infiltration types

注册题目简写:

English Acronym:

研究课题的正式科学名称:

CRSwNP术后复发与中医证型及组织炎性细胞浸润类型相关性的前瞻性研究

Scientific title:

A prospective study on the correlation between postoperative recurrence of CRSwNP and TCM syndrome types and tissue inflammatory cell infiltration types

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100041646 ; ChiMCTR2100004599

申请注册联系人:

罗坤

研究负责人:

谢艳

Applicant:

Luo Kun

Study leader:

Xie Yan

申请注册联系人电话:

Applicant telephone:

+86 18482107500

研究负责人电话:

Study leader's telephone:

+86 15008228100

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cluokunc@163.com

研究负责人电子邮件:

Study leader's E-mail:

xieyan000@cdutcm.edu.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市金牛区十二桥路39号

研究负责人通讯地址:

四川省成都市金牛区十二桥路39号

Applicant address:

39 Twelfth Bridge Road, Jinniu District, Chengdu, Sichuan

Study leader's address:

39 Twelfth Bridge Road, Jinniu District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

610072

研究负责人邮政编码:

Study leader's postcode:

610072

申请人所在单位:

成都中医药大学附属医院

Applicant's institution:

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020KL-048

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

成都中医药大学附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Hospital of Chengdu University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/11/10 0:00:00

伦理委员会联系人:

何清

Contact Name of the ethic committee:

HeQing

伦理委员会联系地址:

四川省成都市金牛区十二桥路39号

Contact Address of the ethic committee:

39 Twelfth Bridge Road, Jinniu District, Chengdu, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28-87783142

伦理委员会联系人邮箱:

Contact email of the ethic committee:

ethicscd@126.com

研究实施负责(组长)单位:

成都中医药大学附属医院

Primary sponsor:

Hospital of Chengdu University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

四川省成都市金牛区十二桥路39号

Primary sponsor's address:

39 Twelfth Bridge Road, Jinniu District, Chengdu, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

具体地址:

金牛区十二桥路39号

Institution
hospital:

Hospital of Chengdu University of Traditional Chinese Medicine

Address:

39 Twelfth Bridge Road, Jinniu District

经费或物资来源:

成都中医药大学杏林学者学科人才科研提升计划

Source(s) of funding:

Chengdu University of Traditional Chinese Medicine Xinglin Scholars Discipline Talent Research Promotion Plan

研究疾病:

慢性鼻窦炎伴鼻息肉

研究疾病代码:

Target disease:

Chronic sinusitis with nasal polyps

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.前瞻性分析不同证型慢性鼻-鼻窦炎伴鼻息肉患者术后复发率差异。 2.通过病理切片对比,探索证型-炎性细胞浸润类型-复发率之间是否存在着明确的相关性及线性推进的生物学效应。

Objectives of Study:

1. Prospectively analyze the difference in postoperative recurrence rate of patients with chronic rhinosinusitis with nasal polyps of different syndromes. 2. Through the comparison of pathological slices, preliminary explore whether there is a clear correlation between the syndrome type-inflammatory cell infiltration type-recurrence rate and the biological effect of linear progression.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)符合欧洲2012年以及我国CRSwNP2018年的诊断标准; 2) 年龄12~75周岁(含12和75周岁),性别不限; 3)准备接受功能性鼻内镜手术; 4)能坚持按期进行常规定期术后处理; 5)能独立完成本研究调查问卷者; 6)同意参加本次试验并签署知情同意书者。

Inclusion criteria

1) Meet the diagnostic criteria of Europe 2012 and my country's CRSwNP 2018; 2) 12 to 75 years old (including 12 and 75 years old), no gender limit; 3) Prepare to undergo functional endoscopic sinus surgery; 4) Able to carry out routine and regular postoperative treatment on schedule; 5) Those who can independently complete this research questionnaire; 6) Those who agree to participate in this trial and sign an informed consent form.

排除标准:

男性或女性患者如符合以下任何一条则不可入选本试验: 1) 变应性真菌性鼻一鼻窦炎,后鼻孔息肉,囊肿,体内寄生虫感染,自身免疫性疾病,免疫缺陷性疾病,严重全身性疾病,精神病患者; 2) 既往接受脱敏治疗; 3) 术前4周内使用抗生素、糖皮质激素、抗组胺药物等治疗; 4) 孕期、哺乳期的妇女; 5) 未能签署试验知情同意书的患者。 凡具有以上任何一条的患者,均予以排除。

Exclusion criteria:

Male or female patients are not eligible for this trial if they meet any of the following: 1) Allergic fungal rhinosinusitis, posterior nostril polyps, cysts, internal parasitic infections, autoimmune diseases, immunodeficiency diseases, severe systemic diseases, and mental patients; 2) Previously received desensitization treatment; 3) Use antibiotics, glucocorticoids, antihistamines and other treatments within 4 weeks before surgery; 4) Women during pregnancy and lactation; 5) Patients who failed to sign the trial informed consent. All patients with any of the above will be excluded.

研究实施时间:

Study execute time:

From 2021-01-06

To      2022-11-10

征募观察对象时间:

Recruiting time:

From 2021-01-06

To      2022-11-11

干预措施:

Interventions:

组别:

根据不同证型分组

样本量:

200

Group:

group according to different syndromes

Sample size:

干预措施:

未涉及

干预措施代码:

Intervention:

Not covered

Intervention code:

样本总量 Total sample size : 200

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Hospital of Chengdu University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

长期疗效

指标类型:

主要指标

Outcome:

Long-term efficacy

Type:

Primary indicator

测量时间点:

手术后1年

测量方法:

Measure time point of outcome:

One year after surgery

Measure method:

指标中文名:

Lund-Kennedy 内镜评分

指标类型:

主要指标

Outcome:

Lund-Kennedy endoscopic score

Type:

Primary indicator

测量时间点:

术后2周、4周、2月、3月、6月、9月及1年。

测量方法:

Measure time point of outcome:

2 weeks, 4 weeks, 2 months, 3 months, 6 months, September and 1 year after operation.

Measure method:

指标中文名:

主观症状VAS评分

指标类型:

主要指标

Outcome:

Subjective symptom VAS score

Type:

Primary indicator

测量时间点:

术后2周、4周、2月、3月、6月、9月及1年。

测量方法:

Measure time point of outcome:

2 weeks, 4 weeks, 2 months, 3 months, 6 months, September and 1 year after operation.

Measure method:

指标中文名:

复发率

指标类型:

主要指标

Outcome:

The recurrence rate

Type:

Primary indicator

测量时间点:

手术后1年

测量方法:

Measure time point of outcome:

One year after surgery

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

鼻息肉组织

组织:

鼻腔息肉

Sample Name:

Nasal polyp tissue

Tissue:

Nasal polyps

人体标本去向

使用后保存

说明

10年

Fate of sample 

Preservation after use

Note:

Ten years

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 12
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not applicable

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统